Gujarat Themis Biosyn Limited , a prominent player in the pharmaceutical intermediates sector, has released its financial results for the first quarter of fiscal year 2026, along with several key corporate announcements.

Financial Performance

The company reported a total income of ₹3,614.72 lakh for the quarter ended June 30, 2025, compared to ₹3,935.17 lakh in the same quarter of the previous year. Despite the slight decrease in revenue, Gujarat Themis Biosyn maintained strong profitability, with a net profit after tax of ₹926.16 lakh. This represents a decrease from the ₹1,323.62 lakh reported in the corresponding quarter of the previous year.

Dividend Record Date

The board of directors has set September 5, 2025, as the record date for determining shareholder eligibility for dividend distribution for the financial year ended March 31, 2025.

Board Composition Changes

Gujarat Themis Biosyn announced significant changes to its board composition:

• New Appointment: Mr. Nihar Parikh has been appointed as an Additional Non-Executive Independent Director, effective August 15, 2025. Parikh, an entrepreneur turned Venture Capitalist, brings valuable experience from his role as CEO of ZCL Chemicals Limited and his current position as founder of 4Point0 Health Ventures.

• Director Cessation: Mr. Siddharth Kusumgar will conclude his tenure as an Independent Director on September 20, 2025, upon completing his second consecutive term.

• Committee Restructuring: Following these changes, Mr. Parikh will replace Mr. Kusumgar on all board committees, including Audit, Nomination & Remuneration, Corporate Social Responsibility, Stakeholders Relationship, and Risk Management Committees, effective September 20, 2025.

New API Plant Commences Operations

In a significant development for the company's growth strategy, Gujarat Themis Biosyn announced the commencement of commercial production at its new Active Pharmaceutical Ingredients (API) plant in Vapi, Gujarat, on May 1, 2025. This state-of-the-art facility is designed to manufacture APIs and intermediates for the pharmaceutical industry, strengthening the company's position in both domestic and export markets, particularly in the United States and Europe.

The new plant is expected to support Gujarat Themis Biosyn's forward integration initiatives and enhance its capabilities in producing fermentation-based pharmaceutical intermediates, which remains the company's core focus.

Gujarat Themis Biosyn's strategic decisions, including the new plant operation and board restructuring, reflect its commitment to growth and adaptation in the evolving pharmaceutical landscape. As the company continues to focus on its strengths in fermentation-based products, investors and industry observers will be keen to watch its performance in the coming quarters.

Gujarat Themis Biosyn Limited , a leading pharmaceutical company, has released its unaudited financial results for the first quarter ended June 30, alongside significant corporate updates.

Financial Performance

The company reported a total income of ₹3,614.72 crore for Q1, compared to ₹3,935.17 crore in the same quarter last year, marking a decrease of 8.14%. Despite the revenue decline, Gujarat Themis Biosyn managed to maintain profitability, with a net profit after tax of ₹926.16 crore. However, this represents a 30.03% decrease from the ₹1,323.62 crore reported in the corresponding quarter of the previous year.

Key Financial Metrics

Dividend Announcement

The board of directors has set September 5 as the record date for determining shareholders' eligibility to receive dividends for the financial year ended March 31.

Board Composition Changes

In a significant move, the company has appointed Mr. Nihar Parikh as an Additional Non-Executive Independent Director, effective August 15. This appointment is subject to shareholder approval at the upcoming Annual General Meeting.

Mr. Parikh brings a wealth of experience to the board. He is the founder of 4Point0 Health Ventures, a fund focused on early-stage health-tech startups in India. His previous roles include serving as the Chief Executive Officer of ZCL Chemicals Limited (Zandu) and holding leadership positions in global pharmaceutical companies.

Concurrently, Mr. Siddharth Kusumgar will conclude his second consecutive term as an Independent Director on September 20. Following these changes, the company will reconstitute its board committees, with Mr. Parikh replacing Mr. Kusumgar on all committees, including Audit, Nomination & Remuneration, Corporate Social Responsibility, Stakeholders Relationship, and Risk Management Committees.

New API Plant Commences Operations

In a strategic move to strengthen its market position, Gujarat Themis Biosyn announced the commencement of commercial production at its new Active Pharmaceutical Ingredients (API) plant in Vapi, Gujarat, on May 1. This state-of-the-art facility is designed for manufacturing APIs and intermediates for the pharmaceutical industry.

The company stated that this new plant would support its forward integration initiatives and bolster its position in export markets, particularly in the United States and Europe. This expansion aligns with Gujarat Themis Biosyn's focus on its core business of fermentation-based pharmaceutical intermediates and APIs.

Gujarat Themis Biosyn's strategic initiatives, including the new API plant and board restructuring, demonstrate the company's commitment to growth and adaptation in the dynamic pharmaceutical market. However, the decline in quarterly revenue and profit suggests that the company may face challenges in the short term, which it aims to address through these strategic moves.

Investors and stakeholders will be keenly watching how these changes impact the company's performance in the coming quarters, especially as the new API plant ramps up production and potentially contributes to revenue growth.